RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
MainPointe Deal Positions RepliCel for entry into the U.S. market and significant milestones in Japan VANCOUVER, BC / ACCESSWIRE /...
Day: January 25, 2021
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief Companies working toward negotiation...